In a seminal review of hypertension trials [1], Verdecchia and coworkers noticed that more intensive compared to usual blood pressure (BP) control reduced major cardiovascular complications (MACE), but that this benefit came at the cost of a higher incidence of adverse events, such as hypotension, electrolyte abnormalities and renal dysfunction. However, given the heterogeneity in the reviewed trials, Verdecchia concluded that the definition of a fixed BP target generalizable to all hypertensive patients is problematic.
